Clinical Trial Results
Research Sponsor: Acerta Pharma B.V., a member of the
AstraZeneca group of companies
Drugs Studied: Acalabrutinib, obinutuzumab, rituximab, and
venetoclax
Trial Purpose: This trial was done to learn how acalabrutinib
works and about its safety when given with
obinutuzumab or rituximab, and with
venetoclax in participants with
chronic lymphocytic leukemia
Protocol Number: ACE-CL-003
Thank you
Thank you to the participants who took part in the clinical trial for the drug
acalabrutinib, given with obinutuzumab or rituximab, and with venetoclax in
participants with chronic lymphocytic leukemia. Acalabrutinib is also called
ACP-196 or Calquence.
Acerta Pharma BV sponsored this trial and believes it is important to share
the results of this trial with the participants and the public. Acerta Pharma BV
reviewed the results of this trial so far and created a report of those results. This is
a summary of that report.
An independent non-profit organization called CISCRP helped prepare this
summary of the trial results. We hope it helps the participants understand and feel
proud of their important role in medical research.
If you participated in this trial and have questions about the results, please speak
with a trial doctor or staff at your trial site.
1